Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

A simple model to assess the probability of invasion in ductal carcinoma in situ of the breast diagnosed by needle biopsy.

Coufal O, Selingerová I, Vrtělová P, Krsička P, Gabrielová L, Fabian P, Stískalová K, Schneiderová M, Poprach A, Justan I.

Biomed Res Int. 2014;2014:480840. doi: 10.1155/2014/480840. Epub 2014 Jul 8.

PMID:
25114904
[PubMed - in process]
Free PMC Article
2.

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.

Buchler T, Bortlicek Z, Poprach A, Kubackova K, Kiss I, Zemanova M, Fiala O, Dusek L, Vyzula R, Melichar B; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 Jul;32(5):569-75. doi: 10.1016/j.urolonc.2013.12.007. Epub 2014 Mar 12.

PMID:
24629497
[PubMed - in process]
3.

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T.

Anticancer Res. 2014 Feb;34(2):949-54.

PMID:
24511038
[PubMed - indexed for MEDLINE]
4.

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8.

PMID:
24321257
[PubMed - in process]
5.

[Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases].

Poprach A, Lakomý R, Selingerová I, Dolečková B, Bílek O, Slabý O, Héžová R, Fabian P, Staník M, Pavlík T, Bortlíček Z, Mlčochová H, Tkáč D, Vyzula R, Kiss I, Kocák I, Kocáková I, Svoboda M.

Klin Onkol. 2013;26(2):114-23. Czech.

PMID:
23718670
[PubMed - indexed for MEDLINE]
6.

[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].

Büchler T, Finek J, Hájek J, Kocák I, Kubácková K, Lakomý R, Melichar B, Petruzelka L, Poprach A, Siffnerová M, Tomásek J, Vyzula R, Zemanová M; Cezkou Kooperativní Skupinu pro Metastický Renální Karcinom.

Klin Onkol. 2013;26(1):55-7. Czech. No abstract available.

PMID:
23607143
[PubMed - indexed for MEDLINE]
7.

MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.

Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O.

Tumour Biol. 2013 Feb;34(1):481-91. doi: 10.1007/s13277-012-0573-2. Epub 2012 Nov 13.

PMID:
23150176
[PubMed - indexed for MEDLINE]
8.

[The RENIS clinical registry].

Poprach A, Büchler T, Bortlíček Z, Dušek L, Vyzula R.

Klin Onkol. 2012;25(4):299-301. Czech. No abstract available.

PMID:
22920173
[PubMed - indexed for MEDLINE]
9.

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.

Buchler T, Pavlik T, Bortlicek Z, Poprach A, Vyzula R, Abrahamova J, Melichar B.

Med Oncol. 2012 Dec;29(5):3321-4. doi: 10.1007/s12032-012-0293-x. Epub 2012 Jun 30.

PMID:
22752573
[PubMed - indexed for MEDLINE]
10.

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.

Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J.

Med Oncol. 2012 Dec;29(5):3314-20. doi: 10.1007/s12032-012-0286-9. Epub 2012 Jun 30.

PMID:
22752571
[PubMed - indexed for MEDLINE]
11.

[Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].

Svoboda M, Navrátil J, Fabian P, Palácová M, Gombošová J, Slámová L, Princ D, Syptáková B, Kudláček A, Bílek O, Pospíšil P, Kazda T, Grell P, Poprach A, Selingerová I, Nenutil R, Juráček J, Héžová R, Slabý O, Vyzula R.

Klin Onkol. 2012;25(3):188-98. Czech. Erratum in: Klin Onkol. 2013;26(2):139.

PMID:
22724568
[PubMed - indexed for MEDLINE]
12.

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group.

Ann Oncol. 2012 Dec;23(12):3137-43. doi: 10.1093/annonc/mds145. Epub 2012 Jun 13.

PMID:
22700990
[PubMed - indexed for MEDLINE]
Free Article
13.

HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma.

Kren L, Valkovsky I, Dolezel J, Capak I, Pacik D, Poprach A, Lakomy R, Redova M, Fabian P, Krenova Z, Slaby O.

Diagn Pathol. 2012 May 29;7:58. doi: 10.1186/1746-1596-7-58.

PMID:
22640987
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.

Svoboda M, Poprach A, Dobes S, Kiss I, Vyzula R.

Cardiovasc Toxicol. 2012 Sep;12(3):191-207. doi: 10.1007/s12012-012-9164-0. Review.

PMID:
22528816
[PubMed - indexed for MEDLINE]
15.

Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients.

Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R.

Genes Chromosomes Cancer. 2012 Jul;51(7):707-16. doi: 10.1002/gcc.21957. Epub 2012 Apr 10.

PMID:
22492545
[PubMed - indexed for MEDLINE]
16.

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.

Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R, Slaby O.

J Transl Med. 2012 Mar 22;10:55. doi: 10.1186/1479-5876-10-55.

PMID:
22440013
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

[Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].

Büchler T, Dusek L, Fínek J, Poprach A, Budnáková D, Kandrnal V, Jarkovský J, Bortlícek Z, Klimes D, Abrahámová J, Vyzula R.

Klin Onkol. 2011;24(5):389-92. Czech. Erratum in: Klin Onkol. 2011;24(6):469.

PMID:
22070021
[PubMed - indexed for MEDLINE]
18.

[Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003-2009].

Lakomý R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarová E, Belanová R, Siková I, Poprach A, Schneiderová M, Procházková M, Sána J, Slabý O, Smrcka M, Vyzula R, Svoboda M.

Klin Onkol. 2011;24(2):112-20. Czech.

PMID:
21644366
[PubMed - indexed for MEDLINE]
19.

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.

Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R.

J Exp Clin Cancer Res. 2010 Jul 7;29:90. doi: 10.1186/1756-9966-29-90. Erratum in: J Exp Clin Cancer Res. 2010;29:105.

PMID:
20609231
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

[Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].

Lakomý R', Greplová K, Pilný R, Budinská E, Valík D, Poprach A, Nemecek R, Vyzula R.

Klin Onkol. 2009;22(5):228-32. Czech.

PMID:
19886361
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk